This is the text extract for PHARMAC, AstraZeneca finalise agreement on goserelin , browse documents here.
Media release PHARMAC, AstraZeneca finalise agreement on goserelin PHARMAC and AstraZeneca have finalised an agreement for the prostate and breast cancer drug goserelin (Zoladex). The agreement will mean that people with prostate cancer and breast cancer will continue to have fully funded access to both goserelin and leuprorelin (Lucrin). Both drugs are approved to treat breast cancer, prostate cancer, endometriosis and precocious puberty. PHARMAC Medical Director Dr Peter Moodie says he is pleased with the outcome of discussions with AstraZeneca that have resulted in patients being able to continue taking both goserelin and leuprorelin, while savings are maintained for taxpayers. ENDS
PHARMAC and AstraZeneca have finalised an agreement for the prostate and breast cancer drug goserelin (Zoladex)...
This text has been extracted from the source PDF document.
Also available as plain text.
Please contact webmaster to discuss alternative format options.